Zydus Lifesciences Q1 Profit Up 31% to Rs 1,420 Cr on Sales Growth
By Rediff Money Desk, New Delhi Aug 09, 2024 15:48
Zydus Lifesciences reported a 31% rise in net profit to Rs 1,420 crore in Q1 FY25 driven by strong sales growth across its businesses, particularly in India and the US.
New Delhi, Aug 9 (PTI) Zydus Lifesciences on Friday said its consolidated net profit increased 31 per cent year on year to Rs 1,420 crore in the first quarter ended June 2024 on the back of robust sales.
The drug maker had reported a net profit of Rs 1,087 crore in the April-June quarter of last fiscal.
Revenue from operations rose to Rs 6,207 crore in the period under review as compared to Rs 5,140 crore in the June quarter of FY24, Zydus Lifesciences said in a statement.
"Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q1 performance," Zydus Lifesciences Managing Director Sharvil Patel said.
Execution success of company's differentiated pipeline in the US and outperformance of India geography business were particularly noteworthy, he added.
"We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions for the future," Patel said.
The company said its India sales stood at Rs 2,212 crore in the June quarter, up 15 per cent, as compared to Rs 1,921 crore in the year-ago period.
The US formulation sales stood at Rs 3,093 crore in first quarter, up 26 per cent year on year as against Rs 2,454 crore in the year-ago period.
Shares of Zydus Lifesciences on Friday ended 1.91 per cent up at Rs 1,304 apiece on the BSE.
The drug maker had reported a net profit of Rs 1,087 crore in the April-June quarter of last fiscal.
Revenue from operations rose to Rs 6,207 crore in the period under review as compared to Rs 5,140 crore in the June quarter of FY24, Zydus Lifesciences said in a statement.
"Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q1 performance," Zydus Lifesciences Managing Director Sharvil Patel said.
Execution success of company's differentiated pipeline in the US and outperformance of India geography business were particularly noteworthy, he added.
"We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions for the future," Patel said.
The company said its India sales stood at Rs 2,212 crore in the June quarter, up 15 per cent, as compared to Rs 1,921 crore in the year-ago period.
The US formulation sales stood at Rs 3,093 crore in first quarter, up 26 per cent year on year as against Rs 2,454 crore in the year-ago period.
Shares of Zydus Lifesciences on Friday ended 1.91 per cent up at Rs 1,304 apiece on the BSE.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Srestha Finvest
- 0.89 ( 0.00)
- 69758135
- Standard Capital
- 1.26 ( -16.00)
- 55792425
- GTL Infrastructure
- 2.37 (+ 4.87)
- 50169700
- Vodafone Idea L
- 9.18 ( -1.50)
- 27130818
- Jaiprakash Power Ven
- 22.33 ( -2.45)
- 21183721
MORE NEWS
Small Finance Bank Profitability to Decline in...
Crisil predicts a decline in profitability for small finance banks (SFBs) in FY25,...
Bullion Rates Today: Gold, Silver Prices in India
Get the latest bullion rates in India. Check today's gold and silver prices per gram...
Sensex Falls 230 Points, Markets Settle Lower...
Indian stock markets closed lower on Friday as investors turned cautious ahead of key...